Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
Journal: Journal of clinical pharmacology
Published: April 26, 2023
Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis.
Journal: Journal of clinical pharmacology
Published: March 11, 2019
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
Journal: Clinical drug investigation
Published: June 28, 2018
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Journal: British journal of clinical pharmacology
Published: May 31, 2018
Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Journal: European journal of clinical pharmacology
Published: March 09, 2018
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Journal: Antimicrobial agents and chemotherapy
Published: October 13, 2017
Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
Journal: Journal of clinical pharmacology
Published: March 01, 2017
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Journal: European journal of clinical pharmacology
Published: October 14, 2016
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Journal: Journal of clinical pharmacology
Published: September 02, 2016
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
Journal: Journal of clinical pharmacology
Published: February 26, 2015
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
Journal: BMC nephrology
Published: August 15, 2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Journal: Metabolism: clinical and experimental
Published: March 12, 2014
Last Updated: 09/26/2026